Article · Wikipedia archive · Last revised Jun 24, 2026

MAL-LAD

MAL-LAD, or MALLAD, also known as METAL-LAD or METALLAD, as well as 6-methallyl-6-nor-LSD, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD).

Last revised
Jun 24, 2026
Read time
≈ 1 min
Length
243 w
Citations
9
Source
Wikipedia ↗
MAL-LAD
Clinical data
Other namesMALLAD; METAL-LAD; METALLAD; 6-Methallyl-6-nor-LSD; N,N-Diethyl-6-(2-methylprop-2-en-1-yl)-9,10-didehydroergoline-8β-carboxamide
Drug classSerotonin receptor agonist
ATC code
  • None
Identifiers
  • (6aR,9R)-N,N-Diethyl-7-(2-methylprop-2-en-1-yl)-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]quinoline-9-carboxamide
Chemical and physical data
FormulaC23H29N3O
Molar mass363.505 g·mol−1
3D model (JSmol)
  • CCN(C(=O)[C@H]1CN(CC(=C)C)[C@H]2C(=C1)c1cccc3c1c(C2)c[nH]3)CC
  • InChI=1S/C23H29N3O/c1-5-25(6-2)23(27)17-10-19-18-8-7-9-20-22(18)16(12-24-20)11-21(19)26(14-17)13-15(3)4/h7-10,12,17,21,24H,3,5-6,11,13-14H2,1-2,4H3/t17-,21-/m1/s1
  • Key:CMBLBLPHJKCTIR-DYESRHJHSA-N

MAL-LAD, or MALLAD, also known as METAL-LAD or METALLAD, as well as 6-methallyl-6-nor-LSD, is a serotonin receptor modulator of the lysergamide family related to lysergic acid diethylamide (LSD).12

The drug acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A receptor among others.12 It is also a dopamine receptor agonist, though unlike other lysergamides, does not show activity at the dopamine D1 and D5 receptors.2 MAL-LAD does not appear to have been assessed in animal tests of psychedelic-like activity such as drug discrimination.1

MAL-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University by 1987.1 It was subsequently further described by a group of researchers that included Nichols and other colleagues in 2025.2 The drug is not a controlled substance in Canada as of 2025.3

See also

See also

References

References

  1. Hoffman AJ (August 1987). Synthesis and pharmacological evaluation of N(6)-alkyl norlysergic acid N,N-diethylamide derivatives (Ph.D. thesis). Purdue University.
  2. Jain MK, Gumpper RH, Slocum ST, Schmitz GP, Madsen JS, Tummino TA, et al. (July 2025). "The polypharmacology of psychedelics reveals multiple targets for potential therapeutics" (PDF). Neuron. doi:10.1016/j.neuron.2025.06.012. PMID 40683247.
  3. "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
External links